Barely Significant
← all excerpts

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.

BMC Cancer · 2024 · PMC10763265 · PMID 38166764

1
hedged sentence
closest p
boldest claim

The sentences

They showed a better trend for survival with chemotherapy rechallenge if time to rechallenge was more than 6 months, but this also did not reach statistical significance. Kostek et al.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.